💨 Abstract

In the second financial quarter, CytomX Therapeutics Inc. (CTMX) reported a loss of $154,000 or less than 1 cent per share, which was significantly lower than analysts' expectations of a 6 cents per share loss. Revenue for the period was $18.7 million, exceeding the anticipated $18.3 million.

Courtesy: WTOP Staff